Latest information on regorafenib manufacturers and prices

Regorafenib (trade name: Byvango), as a new multi-target tyrosine kinase inhibitor, plays an important role in anti-tumor treatment. With the continuous advancement of medical technology and intensified market competition, the manufacturer and price information of regorafenib have also attracted much attention. This article will bring you the latest information on regorafenib manufacturers and prices.

One of the major manufacturers of regorafenib is Bayer AG in Germany (Bayer AG). As a world-renowned pharmaceutical giant, Bayer has strong capabilities in pharmaceutical research and development and production. The regorafenib (Baivango) produced by it has won wide recognition in the market for its excellent efficacy and quality.

In addition to Bayer, there are also many companies launching generic regorafenib drugs in overseas markets. For example, ASEAN Pharmaceuticals in Laos and NATCO Pharmaceuticals in India have launched their own regorafenib products. The launch of these generic drugs provides patients with more choices and also affects the market price of regorafenib to a certain extent.

In terms of price, regorafenib is affected by multiple factors, including manufacturer, drug specifications, sales channels, and region. Currently, the price of regorafenib in the domestic market ranges from several thousand yuan per box. Fortunately, this drug has been included in the medical insurance catalog, and patients can enjoy the medical insurance reimbursement policy. The specific reimbursement ratio varies by region. Generic drugs are sold overseas at very affordable prices. The Laos-ASEAN version of regorafenib costs about more than 600 yuan per box, while India's NATCO Pharmaceuticals' regorafenib costs more than 1,000 yuan, which greatly reduces the burden on patients.

In short, regorafenib is an important anti-tumor drug, and its manufacturer and price information are crucial to patients. As the number of domestic and foreign manufacturers increases and market competition intensifies, the supply of regorafenib will become more abundant and the price will become more reasonable.